| Literature DB >> 24250224 |
Adriana Chassot Bresolin1, Mariana Menegassi Pronsatti, Larissa Nicole Pasqualotto, Patricia Oehlmeyer Nassar, Alex Sandro Jorge, Edson Antonio Alves da Silva, Carlos Augusto Nassar.
Abstract
Due to the biological associations between periodontal and cardiovascular diseases, as well as the fact that atherosclerosis begins in childhood, behavior based on oral health care and metabolic control from an early age is essential for patients with cardiovascular disease. The aim of this research was to examine the effect of full-mouth scaling and root planing on the reduction of periodontal disease in children with congenital heart disease. In this study, treatments were related to clinical periodontal parameters and also to blood ones, such as lipid profile and inflammatory markers. The patients were divided into two groups: group 1 (n=17), scaling and root planing; and group 2 (n=16), full-mouth scaling and root planing. The results showed a significant improvement in clinical periodontal parameters (P<0.05) in both groups. Considering lipid parameters, total cholesterol, triglycerides, and very-low-density lipoprotein parameters showed significant improvement (P<0.05). There was also an improvement in C-reactive protein (ultrasensitive) in the group treated with scaling and root planing (P<0.05). Fibrinogen and interleukin-6 parameters improved (P<0.05) in both groups. We suggest that both periodontal treatments were effective in children with congenital heart disease, though neither demonstrated superiority.Entities:
Keywords: children; congenital; heart defects; inflammation mediators; lipid metabolism; periodontal disease
Mesh:
Substances:
Year: 2013 PMID: 24250224 PMCID: PMC3829709 DOI: 10.2147/VHRM.S52187
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Dental clinical evaluation and statistical significance
| SRP (group 1)
| FMSRP (group 2)
| |||||||
|---|---|---|---|---|---|---|---|---|
| 1st stage (0) | 2nd stage (90 days) | 3rd stage (180 days) | Δ (0–180 days) | 1st stage (0) | 2nd stage (90 days) | 3rd stage (180 days) | Δ (0–180 days) | |
| PI (%) | 46.81 ±0.70 | 47.67±0.64 | 32.65±0.53 | 14.16±0.75 | 39.86±0.40 | 26.97±0.43 | 22.19±0.57 | 17.67±1.00 |
| GI (%) | 7.61 ±0.17 | 8.36±0.17 | 4.13±0.11 | 3.48±0.21 | 5.41±0.12 | 3.08±0.07 | 4.16±0.17 | 1.25±0.15 |
| BOP (%) | 20.25±0.56 | 7.99±0.15 | 6.32±0.15 | 13.93±0.52 | 18.03±0.41 | 5.59±0.24 | 4.51 ±0.16 | 13.52±0.46 |
| PD (mm) | 1.88±0.01 | 1.53±0.01 | 1.39±0.01 | 0.49±0.07 | 1.93±0.01 | 1.50±0.01 | 1.43±0.01 | 0.40±0.10 |
| CAL (mm) | 1.89±0.01 | 1.53±0.01 | 1.40±0.01 | 0.49±0.07 | 1.93±0.01 | 1.50±0.01 | 1.43±0.01 | 0.40±0.10 |
Notes:
Statistically significant difference among means within each of the treatment groups at P<0.05
statistically significant difference between the variation of the means (Δ) of the two treatment groups at P<0.05. Data are expressed as means ± standard error of the mean.
Abbreviations: FMSRP, full-mouth scaling and root planing; PI, plaque index; GI, gingival index; BOP, bleeding on probing; PD, probing depth; CAL, clinical attachment level; SRP, scaling and root planing.
Laboratory evaluation and statistical significance
| SRP (group 1)
| FMSRP (group 2)
| |||||
|---|---|---|---|---|---|---|
| 1st stage (0) | 3rd stage (180 days) | Δ (0–180 days) | 1st stage (0) | 3rd stage (180 days) | Δ (0–180 days) | |
| TC (mg/dL) | 153.76±0.60 | 149.08±0.62 | 4.68±0.55 | 154.80±0.41 | 149.76±0.53 | 5.04±0.54 |
| LDL (mg/dL) | 85.83±0.53 | 90.78±0.70 | −4.95±0.12 | 85.12±0.46 | 81.92±0.62 | 3.20±0.15 |
| HDL (mg/dL) | 51.35±0.32 | 51.57±0.23 | −0.22±0.04 | 54.37±0.44 | 53.53±0.44 | 0.84±0.13 |
| TGs (mg/dL) | 82.94±0.86 | 75.85±0.80 | 7.09±0.83 | 76.93±0.70 | 71.15±0.61 | 5.78±0.86 |
| VLDL (mg/dL) | 16.51±0.17 | 15.21±0.15 | 1.30±0.16 | 15.35±0.14 | 14.30±0.11 | 1.05±0.18 |
| FGN (g/L) | 2.71±0.02 | 2.52±0.01 | 0.19±0.02 | 2.74±0.02 | 2.35±0.01 | 0.39±0.02 |
| CRP (mg/dL) | 0.61±0.04 | 0.20±0.01 | 0.41±0.04 | 0.12±0.01 | 0.20±0.01 | −0.08±0.01 |
| IL-6 (pg/mL) | 1.42±0.09 | 0.85±0.02 | 0.57±0.01 | 0.92±0.02 | 0.72±0.01 | 0.20±0.02 |
| TNF-α (pg/mL) | 12.39±0.9 | 15.79±1.43 | −3.38±0.08 | 13.44±0.70 | 17.73±1.30 | −4.29±0.13 |
Statistically significant difference between means within each of the treatment groups at P<0.05
statistically significant difference between the variation of the means (Δ) of the two treatment groups at P<0.05. Data are expressed as means ± standard error of the mean.
Abbreviations: TC, total cholesterol; HDL, high-density lipoprotein; TGs, triglycerides; VLDL, very-low-density lipoprotein; FGN, fibrinogen; CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factor FMSRP, full-mouth scaling and root planing; SRP, scaling and root planing; LDL, low-density lipoprotein.